SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-007783 to Atreca, Inc. (CIK 0001532346)

Atreca, Inc. (CIK 0001532346)
Date: July 21, 2023 · CIK: 0001532346 · Accession: 0000000000-23-007783

AI Filing Summary & Sentiment

File numbers found in text: 333-273314

Date
July 21, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Atreca, Inc. (CIK 0001532346)

Letter

United States securities and exchange commission logo July 21, 2023 Courtney Phillips General Counsel and Corporate Secretary Atreca, Inc. 835 Industrial Road, Suite 400 San Carlos, CA 94070 Re:Atreca, Inc. Registration Statement on Form S-3 Filed July 18, 2023 File No. 333-273314 Dear Courtney Phillips: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Justin A. Kisner

Show Raw Text
United States securities and exchange commission logo
July 21, 2023
Courtney Phillips
General Counsel and Corporate Secretary
Atreca, Inc.
835 Industrial Road, Suite 400
San Carlos, CA 94070
Re:Atreca, Inc.
Registration Statement on Form S-3
Filed July 18, 2023
File No. 333-273314
Dear Courtney Phillips:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Justin A. Kisner